Phibro Animal Health (PAHC) Reports 24% Sales Growth Driven by Strong Animal Health Demand

Phibro Animal Health Sees Strong Growth Amid Increased Demand for Animal Health Solutions

Phibro Animal Health Corporation (NASDAQ: PAHC) reports notable financial growth for its second quarter ending December 31, 2024, reflecting a robust demand for its products and services in the animal health sector. The company records net sales of $309.3 million, marking a significant $59.3 million increase or a 24% rise compared to the same period in 2023. This surge in sales is largely attributed to heightened demand within the Animal Health segment, which alone contributes $229.4 million in net sales, up 33%. With a 47% increase in sales from the recently integrated Zoetis Medicated Feed Additive (MFA) portfolio, Phibro is effectively capitalizing on new market opportunities.

In addition to sales growth, Phibro's financial metrics show substantial improvement across the board. The company achieves a net income of $3.2 million, an increase of $1.9 million year-over-year, while diluted earnings per share rise to $0.08, up by $0.05. Notably, adjusted EBITDA soars to $48.2 million, reflecting an impressive 64% increase compared to the previous year. These results signal Phibro's successful strategies in enhancing operational efficiencies and leveraging new product lines, positioning the company favorably within a competitive landscape.

Looking forward, Phibro updates its fiscal year 2025 guidance, anticipating net sales between $1.25 billion and $1.30 billion, alongside an adjusted EBITDA of $172 million to $180 million. CEO Jack Bendheim expresses optimism about the company’s trajectory, emphasizing the importance of innovation, strategic initiatives, and disciplined financial management. With continued focus on supporting livestock producers, veterinarians, and consumers, Phibro aims to enhance shareholder value while reinforcing its commitment to animal health and welfare.

In a related development, Phibro Animal Health announces a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. This dividend, payable on March 26, 2025, demonstrates Phibro's financial strength and commitment to returning value to its shareholders. As the company continues to grow and innovate in the animal health sector, it remains dedicated to its mission of providing reliable solutions that promote the health of farm and companion animals worldwide.

Furthermore, the company’s successful integration of the Zoetis Medicated Feed Additive portfolio not only boosts revenue but also showcases Phibro's strategic growth initiatives. This move positions Phibro as a forward-thinking leader in the animal health industry, ready to meet the evolving needs of its customers.